<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BUDESONIDE</span><br/>(bu-des'o-nide)<br/><span class="topboxtradename">Entocort EC, </span><span class="topboxtradename">Pulmicort Turbuhaler, </span><span class="topboxtradename">Rhinocort, </span><span class="topboxtradename">Rhinocort Aqua, </span><span class="topboxtradename">Rhinocort Turbuhaler<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">adrenal corticosteroid</span>; <span class="classification">glucocorticoid</span>; <span class="classification">mineralocorticoid</span><br/><b>Prototype: </b>Hydrocortisone<br/><b>Pregnancy Category: </b>B for inhaled; C for oral<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>32 mcg/inhalation; 3 mg capsule</p>
<h1><a name="action">Actions</a></h1>
<p>Has potent glucocorticoid and weak mineralocorticoid activity. Its antiinflammatory action on nasal mucosa is unknown.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Glucocorticoids have a wide range of inhibitory activities against multiple cell types (e.g., neutrophils, macrophages) and
         mediators (e.g., histamine, cytokines) involved in allergic and nonallergic/irritant-mediated inflammation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of allergic and perennial rhinitis, maintain remission in mild to moderate Crohn's disease; prophylaxis for asthma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to budesonide, lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Concomitant administration of systemic oral steroids; active or quiescent tuberculosis; infections of respiratory tract; in
         sun-treated fungal, bacterial, or systemic viral infections or ocular herpes simplex; recent nasal septal ulcers; recurrent
         epistaxis; nasal surgery or trauma; pregnancy (category C for oral; category B for inhaled). Safety and efficacy for children
         
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Crohn's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 9 mg once/d in a.m. for up to 8 wk, may taper to 6 mg q.d. for 2 wk prior to discontinuing. May repeat 8-wk course for recurring
               episodes of active Crohn's disease.<br/><br/><p><span class="rdpostnotetitle">Asthma Prophylaxis, Rhinitis</span><br/><span class="rdpostnotetext">
<b>See Appendix A-3.</b>
</span></p>
</td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure that capsules are swallowed whole and not chewed.</li>
<li>Give only in the morning.</li>
<li>Patients with moderate to severe liver disease should be monitored for increased signs and/or symptoms of hypercorticism.
            Reducing the dose of Entocort EC capsules should be considered in these patients
         </li>
<li>Store at 25° C (77° F); excursions permitted to 15°30° C (59°86° F)</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Arthralgia, fatigue, fever, hyperkinesis, myalgia, asthenia, paresthesia, tremor. <span class="typehead">CNS:</span> Dizziness, emotional lability, facial edema, nervousness, <span class="speceff-common">headache,</span> agitation, confusion, insomnia, drowsiness. <span class="typehead">CV:</span> Chest pain, hypertension, palpitations, sinus tachycardia. <span class="typehead">GI:</span> Abdominal pain, dyspepsia, gastroenteritis, oral candidiasis, xerostomia, diarrhea, nausea, vomiting, cramps. <span class="typehead">Hematologic:</span> Epistaxis. <span class="typehead">Metabolic:</span> Hypokalemia, weight gain. <span class="typehead">Respiratory:</span> Bronchospasms, <span class="speceff-common">infections,</span> cough, rhinitis, sinusitis, dyspnea, hoarseness, wheezing. <span class="typehead"> Skin:</span>  Eczema, pruritus, purpura, rash, alopecia. <span class="typehead">Special Senses:</span> Contact dermatitis, reduced sense of smell, nasal pain. <span class="typehead">Urogenital:</span> Intermenstrual bleeding, dysuria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Ketoconazole</b> may increase oral budesonide concentrations and toxicity; toxicity may also occur with <b>anastrozole</b> (high doses only), <b>clarithromycin,</b>
<b>cyclosporine,</b>
<b>danazol,</b>
<b>delavirdine,</b>
<b>diltiazem,</b>
<b>erythromycin,</b>
<b>fluconazole,</b>
<b>fluoxetine,</b>
<b>fluvoxamine,</b>
<b>indinavir,</b>
<b>isoniazid,</b>
<b>INH,</b>
<b>itraconazole,</b>
<b>mibefradil,</b>
<b>nefazodone,</b>
<b>nelfinavir,</b>
<b>nicardipine,</b>
<b>norfloxacin,</b>
<b>oxiconazole,</b>
<b>quinidine,</b>
<b>quinine,</b>
<b>ritonavir,</b>
<b>saquinavir,</b>
<b>troleandomycin,</b>
<b>verapamil,</b>
<b>and zafirlukast.</b>
<span class="typehead">Food:</span>
<b>Grapefruit juice</b> will significantly increase bioavailability of oral budesonide. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 20% of nasal inhalation dose, 613% of orally inhaled dose, and 9% of oral dose reaches systemic circulation;
      PO form is absorbed from duodenum at pH &gt;5.5; oral bioavailability increases 2.5 times in hepatic cirrhosis. <span class="typehead">Onset:</span> 812 h inhaled, 2 wk oral. <span class="typehead">Peak:</span> 2 wk inhaled, 8 wk oral delayed by high-fat meal. <span class="typehead">Distribution:</span> 90% protein bound. <span class="typehead">Metabolism:</span> 85% of absorbed dose undergoes first pass metabolism to 2 inactive metabolites by CYP 3A4. <span class="typehead">Elimination:</span> 60% excreted in urine, 40% in feces. <span class="typehead">Half-Life:</span> 23.6 h 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor closely for S&amp;S of hypercorticism if concomitant doses of ketoconazole or other CYP3A4 inhibitors (see Drug Interactions)
            are being given.
         </li>
<li>Monitor patients with moderate to severe liver disease for increased S&amp;S of hypercorticism.</li>
<li>Lab tests: Periodic serum potassium.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify the physician immediately for any of the following: itching, skin rash, fever, swelling of face and neck, difficulty
            breathing, or if you develop S&amp;S of infection.
         </li>
<li>Do not breast feed while taking this drug.</li>
<li>Do not drink grapefruit juice or eat grapefruit regularly.</li>
<li>Avoid people with infections, especially those with chicken pox or measles if you have never had these conditions.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>